Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2017年 / 59卷 / 1529期
关键词：
FIXED-RATIO COMBINATION; LIRAGLUTIDE IDEGLIRA; EFFICACY; OUTCOMES; DEGLUDEC; TRIAL;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：147 / 149
页数：3
相关论文
共 50 条
  • [21] Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
    Rodbard, H. W.
    Buse, J. B.
    Woo, V.
    Vilsboll, T.
    Langbakke, I. H.
    Kvist, K.
    Gough, S. C. L.
    DIABETES OBESITY & METABOLISM, 2016, 18 (01): : 40 - 48
  • [22] Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes
    Vedtofte, Louise
    Knop, Filip K.
    Vilsboll, Tina
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) : 387 - 396
  • [23] Novel combination of insulin degludec and liraglutide (IDegLira) is efficacious across the range of disease progression in type 2 diabetes
    Rodbard, H. W.
    Buse, J. B.
    Woo, V. C.
    Vilsboll, T.
    Langbakke, I.
    Korsholm, L.
    Gough, S.
    DIABETOLOGIA, 2014, 57 : S338 - S339
  • [24] Treatment intensification with insulin degludec improves glycaemic control in patients with Type 2 diabetes treated with liraglutide and metformin
    Kumar, S.
    Aroda, V.
    Bailey, T.
    Cariou, B.
    Leiter, L.
    Raskin, P.
    Zacho, J.
    Philis-Tsimikas, A.
    DIABETIC MEDICINE, 2015, 32 : 66 - 66
  • [25] Addition of liraglutide vs addition of a single dose of insulin aspart to insulin degludec plus metformin in patients with type 2 diabetes
    Mathieu, C.
    Rodbard, H. W.
    Cariou, B.
    Handelsman, Y.
    Philis-Tsimikas, A.
    Francisco, A. Ocampo
    Rana, A.
    Zinman, B.
    DIABETOLOGIA, 2013, 56 : S412 - S413
  • [26] New Xultophy® (insulin degludec/liraglutide; IDegLira) Data Show Improvements in Some Patient Reported Outcomes Versus Glargine
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2015, 17 (11): : 1105 - 1106
  • [27] EFFICACY AND SAFETY OF INSULIN DEGLUDEC 200 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES (BEGIN: COMPARE)
    Bode, Bruce W.
    Chaykin, Louis B.
    Sussman, Allen M.
    Warren, Mark L.
    Niemeyer, Marcus
    Rabol, Rasmus
    Rodbard, Helena W.
    ENDOCRINE PRACTICE, 2014, 20 (08) : 785 - 791
  • [28] Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
    Liu, Hongzhong
    Luo, Bin
    Chen, Xia
    Ingwersen, Steen H.
    Jia, Ting
    Jacobsen, Lisbeth Vestergard
    Hu, Pei
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (04) : 652 - 656
  • [29] Converting to Insulin Degludec/Liraglutide (IDegLira) Is Efficacious Regardless of Pretrial Insulin Dose in Patients with Type 2 Diabetes (T2D) Uncontrolled on Insulin Glargine U100 (IGlar)
    Meneghini, Luigi F.
    Jaeckel, Elmar
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Harvey, John N.
    Begtrup, Kamilla
    Chandarana, Keval
    Vilsboll, Tina
    DIABETES, 2017, 66 : A289 - A289
  • [30] Efficacy and safety of a combination of insulin degludec and liraglutide (IDegLira) in patients with Type 2 diabetes after 1 year of treatment
    Gough, S. C. L.
    Woo, V. C.
    Rodbard, H. W.
    Linjawi, S.
    Poulsen, P.
    Korsholm, L.
    Bode, B. W.
    DIABETIC MEDICINE, 2015, 32 : 76 - 76
12345